Acrivon Therapeutics, Inc. Common Stock (ACRV) NASDAQ

1.91

+0.05(+2.69%)

Updated at October 03 04:00PM

Currency In USD

Acrivon Therapeutics, Inc. Common Stock

Address

480 Arsenal Way

Watertown, MA 02472

United States of America

Phone

617-207-8979

Sector

Healthcare

Industry

Biotechnology

Employees

75

First IPO Date

November 15, 2022

Key Executives

NameTitlePayYear Born
Dr. Peter Blume-Jensen M.D., Ph.D.Co-Founder, Chairman of the Board, Chief Executive Officer, President & Acting Chief Scientific Officer1.07M1963
Dr. Erick Gamelin M.D., Ph.D.Chief Development Officer480,7231958
Ms. Mary-Alice Miller J.D.Chief Legal Officer & Corporate Secretary587,1081974
Dr. Eric J. Devroe Ph.D.Chief Operating Officer774,0261979
Ms. Kristina Masson M.B.A., Ph.D.Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer & Director824,4741981
Dr. Adam D. Levy M.B.A., Ph.D.Chief Financial Officer & Principal Financial Officer01966
Ms. Katharine Peterson CPAVice President of Finance & Accounting0N/A
Mr. Joon Jung Ph.D.Vice President & Head of Data Science0N/A
Dr. Jesper V. Olsen Ph.D.Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board0N/A
Mr. Bruce CloseVice President of Quality & Compliance0N/A

Description

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.